|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||13.07 - 13.56|
|52 Week Range||10.87 - 26.25|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.57|
SAN DIEGO, Nov. 14, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2019 London Healthcare.
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
Retrophin (RTRX) delivered earnings and revenue surprises of 22.73% and -2.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 16, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2019 financial results on Wednesday, October 30, 2019 after the close of.
Retrophin, Inc. (RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2019. The Company and its collaborators will also present preclinical findings suggesting that treatment with sparsentan may present a unique therapeutic approach to reducing both renal injury and hearing loss in patients with Alport syndrome. FSGS and Alport syndrome are rare, progressive kidney disorders that often lead to end-stage renal disease (ESRD).
Retrophin, Inc. (RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma will be responsible for leading Retrophin’s commercial organization and developing the company’s commercialization strategy for approved products and pre-commercial planning for pipeline programs, including sparsentan, which is currently being evaluated in Phase 3 clinical trials for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Mr. Heerma will report to president and chief executive officer Dr. Eric Dube.
If you own shares in Retrophin, Inc. (NASDAQ:RTRX) then it's worth thinking about how it contributes to the volatility...
SAN DIEGO, Sept. 26, 2019 -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare.
Retrophin stock collapsed to a three-year low Thursday after the biotech company's treatment for a rare nervous system disease failed in a Phase 3 test. The drug missed two key goals.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...
Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients' ability to conduct daily activities such as eating and walking, sending shares down 30%. The treatment, fosmetpantotenate, was being tested against placebo in 84 patients with pantothenate kinase-associated neurodegeneration (PKAN), a rare, genetic and life-threatening disorder. "We have realized that this is a failed study with no difference to placebo," Chief Executive Officer Eric Dube said.
Retrophin, Inc. (RTRX) today announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary endpoint and did not demonstrate a difference between treatment groups. “We are very disappointed in the topline results from the FORT Study, particularly because we have seen the devastating impact of PKAN on patients and their families, and a significant unmet need remains with no approved treatment option.